Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$62.00 USD
-1.31 (-2.07%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $61.80 -0.20 (-0.32%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
VKTX 62.00 -1.31(-2.07%)
Will VKTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VKTX
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
Other News for VKTX
Lilly looking to test Zepbound as health maintenance drug: report
New small-cap buy and sell ideas for Oppenheimer’s 50/50 list
Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report
Buy Rating Affirmed for Viking Therapeutics as VK2735 Shows Promise in Obesity Treatment
Voya MidCap Opportunities Strategy Q2 2024 Commentary